Research Use Only Application: Antibody conjugation reagent for Targeted cell death, Targeted cell death for cancer cells, High-throughput screening with cell killing assays oYo-Link DM4 is an Antibody-Drug Conjugation reagent allowing for site-specific labeling of DM4 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link limits the attachment of the DM4 drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DM4 drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent ravtansine, also known as the maytansinoid DM4, the DM4 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with ravtansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link DM4 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins. Catalog AT7004 Requirements: To label your compatible antibodies with oYo-Link, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaTheras LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support alphathera.com
Concentration:
270 µg/mL
Molecular Weight:
8 kDa
Buffer:
PBS
Form:
Dried pellet
* VAT and and shipping costs not included. Errors and price changes excepted
